Lung cancer kills more people worldwide than other malignancy. Currently 33,500 individuals die each year in the UK from lung cancer. The number of deaths has fallen in the past years and this is likely to be due to a decline in tobacco smoking, and possibly greater public awareness. However, there is now a large ex-smoking population in the USA and Europe, who remain at high risk of developing lung cancer, which is dependent on their smoking duration prior to tobacco cessation. This group of individuals now exceeds current smokers in both the USA and Europe and will continue to do so over the next two to three decades. The Roy Castle Lung Cancer Research team have developed methods of identifying  individuals who are at risk of the disease and are developing new early lung cancer diagnostic biomarkers. In addition the research team is at the forefront of molecular-genetic technologies aiming to understand the basic molecular mechanism in the developing lung cancer.  The research group are working with national and International collaborators on the clinical evaluation of early lung disease as well and utilising the forefront technologies of genomics, methylation profiling and second generation sequencing.




Screening to detect the disease before patients develop any symptoms is a control measure urgently requiring evaluation as surgical resection at an early stage of the disease remains the only realistic option for a cure.


Designed & Developed By: AN Computing